216 related articles for article (PubMed ID: 15059133)
41. A new mechanism of leukemia drug resistance?
Williams DA
N Engl J Med; 2007 Jul; 357(1):77-8. PubMed ID: 17611211
[No Abstract] [Full Text] [Related]
42. Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase.
Goursaud L; Berthon C; Quesnel B
Br J Haematol; 2023 Feb; 200(4):e37-e39. PubMed ID: 36470305
[No Abstract] [Full Text] [Related]
43. Asparaginase use for the treatment of acute lymphoblastic leukemia.
Barba P; Dapena JL; Montesinos P; Rives S
Med Clin (Barc); 2017 Mar; 148(5):225-231. PubMed ID: 28118965
[No Abstract] [Full Text] [Related]
44. [Progress in researches on L-asparaginase targeted to childhood leukemia].
Cui YQ; Chen FX; Wu ZL
Zhonghua Er Ke Za Zhi; 2004 Mar; 42(3):227-30. PubMed ID: 15144726
[No Abstract] [Full Text] [Related]
45. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.
Matsuzaki A; Suminoe A; Hara T
Pediatr Hematol Oncol; 2002 Dec; 19(8):601-3. PubMed ID: 12487838
[TBL] [Abstract][Full Text] [Related]
46. Asparaginase in acute lymphoblastic leukemia.
Kawedia JD; Rytting ME
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
[TBL] [Abstract][Full Text] [Related]
47. Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Pinheiro JP; Lanvers C; Würthwein G; Boos J
Blood; 2002 Sep; 100(5):1923-4; author reply 1924-5. PubMed ID: 12211194
[No Abstract] [Full Text] [Related]
48. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia.
Estlin EJ; Ronghe M; Burke GA; Yule SM
Br J Haematol; 2000 Sep; 110(4):780-90. PubMed ID: 11054059
[No Abstract] [Full Text] [Related]
49. High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?
Kamen BA
J Pediatr Hematol Oncol; 2004 Jun; 26(6):333-5. PubMed ID: 15167344
[No Abstract] [Full Text] [Related]
50. Asparaginase activity monitoring experience from the Maritimes, Canada.
Pike M; Kulkarni K; MacDonald T
Leuk Lymphoma; 2019 Sep; 60(9):2312-2315. PubMed ID: 30721104
[No Abstract] [Full Text] [Related]
51. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
52. Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
Chen SH
Pediatr Neonatol; 2015 Oct; 56(5):287-93. PubMed ID: 25603726
[TBL] [Abstract][Full Text] [Related]
53. L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): A novel approach to target ALL.
Ali U; Naveed M; Ullah A; Ali K; Shah SA; Fahad S; Mumtaz AS
Eur J Pharmacol; 2016 Jan; 771():199-210. PubMed ID: 26698391
[TBL] [Abstract][Full Text] [Related]
54. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
[TBL] [Abstract][Full Text] [Related]
55. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
56. Reply to: Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia".
McCormick M; Friehling E; Smith K
Pediatr Blood Cancer; 2022 Nov; 69(11):e29694. PubMed ID: 35338677
[No Abstract] [Full Text] [Related]
57. Pancreatic panniculitis caused by L-asparaginase induced acute pancreatitis in a child with acute lymphoblastic leukemia.
Chiewchengchol D; Wananukul S; Noppakun N
Pediatr Dermatol; 2009; 26(1):47-9. PubMed ID: 19250405
[TBL] [Abstract][Full Text] [Related]
58. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Peters BG; Goeckner BJ; Ponzillo JJ; Velasquez WS; Wilson AL
Formulary; 1995 Jul; 30(7):388-93. PubMed ID: 10151730
[TBL] [Abstract][Full Text] [Related]
59. Atypical pyoderma gangrenosum as a manifestation of childhood acute lymphoblastic leukemia.
Bakhshi S; Sethuraman G; Singh MK; Arya LS
Pediatr Dermatol; 2005; 22(6):543-5. PubMed ID: 16354258
[TBL] [Abstract][Full Text] [Related]
60. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
